MedTrace Logo

Towards a Functional Cure for HBV - The COMMIT Cohort Study

NCT03645044 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2025-07-17

No results posted yet for this study

Summary

Hepatitis B virus (HBV) infection can be treated, but therapy is usually lifelong and has side effects, so a cure for HBV is a critical endpoint. This study examines the key steps to HBV cure in the setting of HIV-HBV co-infection, where rates of development of antibodies against HBV after starting HBV treatment are higher than in people with HBV alone starting treatment. In Asia both HBV and HIV are common so this provides a unique opportunity to study HBV. We will investigate how an effective immune response against the two main HBV proteins is developed. If we can understand how the immune response works against HBV, this could be used to develop new therapies towards a cure for HBV

Conditions

  • Hiv
  • HBV Coinfection

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • The University of Western Australia

    collaborator OTHER

  • University of Adelaide

    collaborator OTHER

  • The HIV Netherlands Australia Thailand Research Collaboration

    collaborator OTHER

  • University of Malaya

    collaborator OTHER

  • YR Gaitonde Centre for AIDS Research and Education

    collaborator OTHER

  • Melbourne Health

    collaborator OTHER

  • University of Melbourne

    lead OTHER

Principal Investigators

  • Joe Sasadeusz, MBBS, PhD · University of Melbourne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-24
Primary Completion
2022-04-29
Completion
2025-07-31

Countries

  • India
  • Malaysia
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03645044 on ClinicalTrials.gov